CelLBxHealth plc Stock
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Delayed
London S.E.
11:44:42 29/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.6440 GBX | +3.04% |
|
+3.04% | -41.45% |
| 10-21 | CelLBxHealth warns of revenue timing delays amid commercial progress | AN |
| 10-21 | WINNERS & LOSERS: Mobico and Ashtead surge on takeover news | AN |
| Market Cap | 7.1M 9.45M 8.48M 7.84M 13.27M 900M 13.43M 93.77M 37.35M 471M 35.48M 34.73M 1.5B | P/E 2026 * |
-0.27x | P/E 2027 * | -4.03x |
|---|---|---|---|---|---|
| Enterprise Value | 5.8M 7.72M 6.93M 6.41M 10.84M 736M 10.97M 76.6M 30.51M 385M 28.98M 28.37M 1.22B | EV / Sales 2026 * |
0.39x | EV / Sales 2027 * | 0.4x |
| Free-Float |
95.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| CLBX | Delayed | |
OTC Markets
| ANPCF | Delayed | |
|
Deutsche Boerse AG
| DWV | Delayed |
Last Transcript: CelLBxHealth plc
| 16/10/25 | Angle names Peter Collins as interim CEO | AN |
| 28/05/25 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/01/25 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/09/23 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/01/22 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 day | +3.04% | ||
| 1 week | +3.04% | ||
| Current month | -24.24% | ||
| 1 month | -26.40% | ||
| 3 months | -49.49% | ||
| 6 months | -30.38% | ||
| Current year | -41.45% |
| 1 week | 0.55 |  | 0.64 |
| 1 month | 0.53 | | 1 |
| Current year | 0.53 | | 2.8 |
| 1 year | 0.53 | | 2.8 |
| 3 years | 0.53 | | 37.4 |
| 5 years | 0.53 | | 163.75 |
| 10 years | 0.53 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 01/01/1999 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2025 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 05/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 22/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 12/01/2026 |
| Director/Board Member | 61 | 12/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/19/25 A | Buy | Chief Executive Officer | 5,000,000 | 1.5497% | ||
| 12/19/25 A | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 12/19/25 A | Buy | Chairman | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.04% | +3.04% | -70.73% | -94.40% | 9.45M | |
| -0.23% | +1.46% | +26.28% | +63.22% | 260B | |
| +0.09% | +0.09% | +7.92% | +24.58% | 165B | |
| +0.30% | +3.75% | -18.56% | +71.51% | 154B | |
| -0.28% | -4.67% | -57.98% | -14.32% | 61.49B | |
| +1.77% | +3.82% | +11.67% | +48.73% | 52.9B | |
| +0.68% | +2.71% | -13.09% | -6.29% | 52.84B | |
| -1.36% | -0.85% | +9.09% | +67.70% | 51.46B | |
| -0.22% | +2.10% | +24.43% | +76.59% | 51.16B | |
| -0.28% | +4.24% | +37.85% | +94.84% | 46.85B | |
| Average | +0.29% | +0.46% | -4.31% | +33.22% | 89.57B | |
| Weighted average by Cap. | -0.07% | +1.41% | +5.74% | +49.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.03M 20.01M 17.95M 16.6M 28.09M 1.91B 28.43M 198M 79.05M 997M 75.09M 73.51M 3.17B | 26.2M 34.88M 31.29M 28.93M 48.95M 3.32B 49.54M 346M 138M 1.74B 131M 128M 5.52B |
| Net income | -8.6M -11.45M -10.27M -9.5M -16.07M -1.09B -16.26M -114M -45.22M -571M -42.96M -42.05M -1.81B | -2.6M -3.46M -3.11M -2.87M -4.86M -330M -4.92M -34.32M -13.67M -172M -12.99M -12.71M -548M |
| Net Debt | -1.3M -1.73M -1.55M -1.44M -2.43M -165M -2.46M -17.16M -6.84M -86.24M -6.49M -6.36M -274M | 3.3M 4.39M 3.94M 3.64M 6.17M 418M 6.24M 43.57M 17.35M 219M 16.48M 16.14M 695M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | GBX 0.6440 | +3.04% | 23,514 |
| 28/10/26 | GBX 0.6250 | +4.17% | 4,057,423 |
| 27/10/26 | GBX 0.6000 | 0.00% | 624,929 |
| 26/10/26 | GBX 0.6000 | 0.00% | 1,211,020 |
| 23/10/26 | GBX 0.6000 | -4.00% | 2,061,906 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
